| 产品名称： | FL74-UCD-1 |
|---|---|
| 商品货号： | TS212154 |
| Organism： | Felis catus, cat |
| Cell Type： | lymphoblast |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | leukemia |
| Applications： | The cells are capable of producing large amounts of feline leukemia that has attenuated virulence for cats, but which is capable of being used for vaccine preparation. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | The line was established from the lymphomatous kidney of a cat that had been inoculated with virus obtained by serial cell free passage of virus from a cat with spontaneous leukemia. |
| Genes Expressed： | Feline leukemia virus (FeLV), KT-FeLV-UCD-1 strain |
| Cellular Products： | Feline leukemia virus (FeLV), KT-FeLV-UCD-1 strain |
| Comments： | These cells are persistently infected with the KT-FeLV-UCD-1 feline leukemia virus. The line was established from the lymphomatous kidney of a cat that had been inoculated with virus obtained by serial cell free passage of virus from a cat with spontaneous leukemia. The cells are capable of producing large amounts of feline leukemia that has attenuated virulence for cats, but which is capable of being used for vaccine preparation. |
| Complete Growth Medium： | Leibovitzs L-15 medium with 2mM L-glutamine, 85%; fetal bovine serum, 15% (Note: The L-15 medium formulation was devised for use in a free gas exchange with atmospheric air. A CO2 and air mixture is detrimental to cells when using this medium for cultivation). |
| Subculturing： | Subcultivation Ratio: A subcultivation ratio of 1:4 is recommended Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation： | Culture medium, 95%; DMSO, 5% |
| Name of Depositor： | NC Pedersen |
| Deposited As： | Felis catus |
| U.S. Patent Number： | |
| Passage History： | The line was established from the lymphomatous kidney of a cat that had been inoculated with virus obtained by serial cell free passage of virus from a cat with spontaneous leukemia. |
| References： | Pedersen NC, Theilen GH. Vaccine for preventing persistent feline leukemia viremia in cats. US Patent 4,264,587 dated Apr 28 1981 Theilen GH, et al. Replication of cat leukemia virus in cell suspension cultures. Nature 222: 589-590, 1969. PubMed: 5818677 Pedersen NC, et al. Safety and efficacy studies of live- and killed-feline leukemia virus vaccines. Am. J. Vet. Res. 40: 1120-1126, 1979. PubMed: 230767 |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | FL74-UCD-1 |
|---|---|
| 商品货号： | TS212154 |
| Organism： | Felis catus, cat |
| Cell Type： | lymphoblast |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | leukemia |
| Applications： | The cells are capable of producing large amounts of feline leukemia that has attenuated virulence for cats, but which is capable of being used for vaccine preparation. |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation： | The line was established from the lymphomatous kidney of a cat that had been inoculated with virus obtained by serial cell free passage of virus from a cat with spontaneous leukemia. |
| Genes Expressed： | Feline leukemia virus (FeLV), KT-FeLV-UCD-1 strain |
| Cellular Products： | Feline leukemia virus (FeLV), KT-FeLV-UCD-1 strain |
| Comments： | These cells are persistently infected with the KT-FeLV-UCD-1 feline leukemia virus. The line was established from the lymphomatous kidney of a cat that had been inoculated with virus obtained by serial cell free passage of virus from a cat with spontaneous leukemia. The cells are capable of producing large amounts of feline leukemia that has attenuated virulence for cats, but which is capable of being used for vaccine preparation. |
| Complete Growth Medium： | Leibovitzs L-15 medium with 2mM L-glutamine, 85%; fetal bovine serum, 15% (Note: The L-15 medium formulation was devised for use in a free gas exchange with atmospheric air. A CO2 and air mixture is detrimental to cells when using this medium for cultivation). |
| Subculturing： | Subcultivation Ratio: A subcultivation ratio of 1:4 is recommended Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Cryopreservation： | Culture medium, 95%; DMSO, 5% |
| Name of Depositor： | NC Pedersen |
| Deposited As： | Felis catus |
| U.S. Patent Number： | |
| Passage History： | The line was established from the lymphomatous kidney of a cat that had been inoculated with virus obtained by serial cell free passage of virus from a cat with spontaneous leukemia. |
| References： | Pedersen NC, Theilen GH. Vaccine for preventing persistent feline leukemia viremia in cats. US Patent 4,264,587 dated Apr 28 1981 Theilen GH, et al. Replication of cat leukemia virus in cell suspension cultures. Nature 222: 589-590, 1969. PubMed: 5818677 Pedersen NC, et al. Safety and efficacy studies of live- and killed-feline leukemia virus vaccines. Am. J. Vet. Res. 40: 1120-1126, 1979. PubMed: 230767 |
